Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6) is a synthesized compound combining a Thalidomide-based cereblon ligand with a linker, serving as an E3 ligase ligand-linker conjugate for the synthesis of PROTACs[1].

Thalidomide-O-amido-C4-NH2, also known as Compound 41, serves as an amine intermediate in the synthesis of heterobifunctional PROTAC BET degraders. These degraders target the bromodomain and extra-terminal (BET) family of proteins—BRD2, BRD3, BRD4, and BRDT—which are crucial in gene transcription regulation and are attractive therapeutic targets for cancer and other diseases. Utilizing the proteolysis targeting chimera (PROTAC) approach, these small molecules induce the degradation of BET proteins. Specifically, Thalidomide-O-amido-C4-NH2 functions as a degron-linker (Compound DL6-TL), a structure that covalently links a degron to a targeting ligand. The degron binds to an E3 ubiquitin ligase (e.g., cereblon), facilitating the targeted degradation of the protein(s) bound by the targeting ligand.